Variables	Input Parameters during a 3-Year Period (6 Cycles) Post-LOE (%)a
	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5	Cycle 6
Greece
Hospital
Market share of generics/biosimilar (%)	20	40	50	60	70	70
Market growth/expansion post-LOE (%)	0	0	0	0	0	0
Post-LOE expected price level of branded productb	100	93	93	87	87	80
Post-LOE expected price level of generics/biosimilarsb	65	61	61	56	56	52
Retail
Market share of generics/biosimilar (%)	10	20	40	50	60	60
Market growth/expansion post-LOE (%)	0	0	0	0	0	0
Post-LOE expected price level of branded productb	65	61	61	56	56	52
Post-LOE expected price level of generics/biosimilarsb	65	61	61	56	56	52
The Netherlands
Biological products (hospital or retail)c
Market share of generics/biosimilar (%)	50	50	70	70	80	80
Market growth/expansion post-LOE (%)	0	0%	0	0	0	0
Post-LOE expected price level of branded productb	70	70	50	50	40	40
Post-LOE expected price level of generics/biosimilarsb	50	50	30	30	30	30
Small molecules (hospital or retail)c
Market share of generics/biosimilar (%)	50	50	70	70	80	80
Market growth/expansion post-LOE (%)	0	0	0	0	0	0
Post-LOE expected price level of branded productb	50	50	40	40	40	40
Post-LOE expected price level of generics/biosimilarsb	30	30	20	20	20	20
Norway
Hospital
Market share of generics/biosimilar (%)	60	70	80	90	90	90
Market growth/expansion post-LOE (%)	0	0	0	0	0	0
Post-LOE expected price level of branded productb	54	54	54	54	54	54
Post-LOE expected price level of generics/biosimilarsb	54	54	54	54	54	54
Retail
Market share of generics/biosimilar (%)	60	70	80	90	90	90
Market growth/expansion post-LOE (%)	0	0	0	0	0	0
Post-LOE expected price level of branded productb	65	41	41	41	41	41
Post-LOE expected price level of generics/biosimilarsb	65	41	41	41	41	41
Sweden
Hospital
Market share of generics/biosimilar (%)	60	100	100	100	100	100
Market growth/expansion post-LOE (%)	0	0	0	0	0	0
Post-LOE expected price level of branded productb	60	50	30	30	30	30
Post-LOE expected price level of generics/biosimilarsb	60	50	30	30	30	30
Retail
Market share of generics/biosimilar (%)	60	100	100	100	100	100
Market growth/expansion post-LOE (%)	0	0	0	0	0	0
Post-LOE expected price level of branded productb	100	35	35	35	35	35
Post-LOE expected price level of generics/biosimilarsb	20	10	10	10	10	10